Sector News

PDL goes public with hostile bid to buy Neos

October 30, 2017
Life sciences

PDL BioPharma has gone public with its attempt to buy Neos Therapeutics. The investment group told the world of its desire to buy the ADHD specialist after twice being rebuffed.

Incline Village, Nevada-based PDL put a $10.25-a-share offer to Neos in June. Days later, Neos carried out a dilutive financing at $6.25 share. That meant, all else being equal, PDL would have to pay more to buy Neos. Despite that, PDL kept its bid at $10.25 a share. Neos’ board recently rejected that second, effectively improved offer.

PDL has now gone public with its plans, a move it says was motivated by Neos’ “board’s refusal to negotiate in good faith toward a transaction.” The $10.25-a-share offer represents a 40% premium over Neos’ stock price just before news of PDL’s plans broke. Neos’ stock rose more than 35% on the back of the news, closing just shy of the offer price at $10.05.

If PDL can complete the deal, it will add two approved drugs and one near-market pipeline prospect to its portfolio. Neos has built its business on extended-release and orally disintegrating tablet technologies. The technologies underpin its approved pediatric formulations of amphetamine and methylphenidate, as well as a second amphetamine formulation that is awaiting approval by the FDA.

PDL’s pitch to Neos is based on a belief that its resources can accelerate adoption of these products and the development of new drugs based on the same technologies. That pitch, and the cash tied to it, failed to woo Neos’ board. The question now is whether dialing up the pressure on Neos will deliver a breakthrough.

The board unanimously rejected both of the earlier offers on the grounds they failed to reflect its “strategic value and future prospects for continued growth and value creation.” Neos’ board is now considering the latest offer. But, given the board felt the last $10.25-a-share offer “substantially undervalued” the company, it is questionable whether its position will change.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).